Comparison of Long-Term Prognostic Value of N-terminal-proBNP and Midregional-pro-Adrenomedullin in Patients with Acute Myocardial Infarction
Walter, T.; Brueckmann, M.; Lang, S.; Sauer, T.; Fiedler, E.; Papassotiriou, J.; Behnes, M.; Elmas, E.; Borggrefe, M.; Bertsch, T.
Clinical Laboratory 56(7-8): 303-309
2010
ISSN/ISBN: 1433-6510 PMID: 20857894 Document Number: 11689
Background: N-terminal-proBNP (NT-proBNP) and Midregional-pro-Adrenomedullin (MR-proADM) predict mortality of patients with acute myocardial infarction (AMI). Comparison of the prognostic values of NT-proBNP and MR-proADM to predict long-term adverse clinical events (AE) after AMI has not been evaluated yet. Methods: 30 patients with AMI were enrolled into this prospective study. Measurements of NT-proBNP and MR-proADM were performed at initial presentation, two or three days and four months after AMI. Long-term AE defined as recurrent AMI, need for repeated percutaneous transluminal angioplasty or coronary bypass graft surgery, congestive heart failure, cardiopulmonary resuscitation, cardiogenic shock, syncope, and death were documented during a follow-up period of ten months. Results: At initial presentation, NT-proBNP values were significantly higher in patients with AE compared to patients without AE (p Conclusions: Early measurements of NT-proBNP or MR-proADM during the acute phase of AMI may allow the risk of a long-term AE to be excluded, based on the comparable test characteristics,.
Document emailed within 1 workday
